Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Biogen

Benzinga's Top Ratings Upgrades, Downgrades For October 26, 2022

Upgrades

Benzinga

Biogen Whale Trades For October 20

A whale with a lot of money to spend has taken a noticeably bearish stance on Biogen. Looking at options history for Biogen (NASDAQ:BIIB) we detected 12 strange trades.

Benzinga

For Alzheimer’s patients, a controversial drug brings hope

TAMPA, Fla. -- At 53, Michele Hall was at the height of her legal career. She’d just sent her three kids to college. She had decades ahead with her husband Doug — after nearly 30 years of marriage, the couple looked forward to celebrating 30 more.

Tribune News Service

From analysis to the latest developments in health,
read the most diverse news in one place.

This Is What Whales Are Betting On Biogen

Someone with a lot of money to spend has taken a bearish stance on Biogen (NASDAQ:BIIB). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2022

Upgrades

Benzinga

2 Stocks with Great Track Records to Buy Right Now

Despite the Fed's aggressive interest rate hikes, the job market remains strong. However, given the mounting recessionary fears, it may be prudent to invest in UnitedHealth Group (UNH) and Biogen (BIIB), based on their solid fundamentals and impressive growth prospects. Continue Reading….

StockNews.com

Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2022

Upgrades

Benzinga

Read news from The Economist, FT, and more,
with one subscription

New Alzheimer's drug slows cognitive decline – and may be available as early as next year

Lecanemab is the first drug to help improve the symptoms of Alzheimer’s by slowing the disease. These are very promising results, although the only data we have at the moment is from the drugmaker’s press release.

The Conversation

Mayo Clinic expert offers perspective on experimental Alzheimer's disease drug

According to drugmakers Eisai and Biogen, a Phase 3 clinical study on a potential new Alzheimer's disease drug shows promise. The study findings show that the drug, lecanemab, reduced clinical decline of people with Alzheimer's disease by 27% compared with a placebo after 18 months of treatment.

Tribune News Service

‘Historic moment’: Drug slows cognitive decline in Alzheimer’s

It's being widely reported that an experimental drug has slowed the cognitive decline and brain damage in Alzheimer's patients.

The New Daily

5 bits of good news you might have missed this week - including Alzheimer's breakthrough

The news has been pretty bleak lately and it's been hard to keep up with all the sombre events that have been going on, so you may have missed a few stories that could make you a bit more hopeful for the future

Daily Mirror

Market Wrap: Volatility continues with pound’s flash-crash and a bearish US dollar

Volatility expected to remain heightened (in ‘both directions’) until the Fed manages to get inflation back under control.

The New Daily

Another prospect for an Alzheimer's drug renews cost concerns

But positive clinical trial results also renew the hopes of millions of seniors.

Axios

Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday

Gainers PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The trial met its primary endpoint.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Netflix, Biogen And Other Big Gainers From Wednesday

U.S. stocks closed higher with the Dow Jones surging more than 500 points on Wednesday. Here is the list of some big stocks recording gains in the previous session.

Benzinga

These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win

Eli Lilly And Co (NYSE:LLY) - Market cap: $295 billion.

Benzinga

What The Biogen Chart Reveals As Stock Rallies Hard On Alzheimer's Data

Going back to at least December 2014, Biogen Inc (NASDAQ: BIIB) has been diligently working on drugs to cure Alzheimer's disease. Both the negative and positive data revealed over the years have instigated wild price gyrations in the issue.

Benzinga

Nasdaq Surges Over 150 Points; Gold Rises 2%

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 400 points on Wednesday.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Why Prothena Corporation Shares Are Trading Higher By 76%, Here Are 53 Stocks Moving In Wednesday's Mid-Day Session

Gainers

Benzinga

7 Biogen Analysts On Alzheimer's Drug Success As Stock Skyrockets 37%

Shares of Biogen Inc (NASDAQ: BIIB) were flying on Wednesday, after the biopharma company said its experimental Alzheimer’s drug with Japanese partner Eisai showed promising results. RBC Capital Markets On Biogen

Benzinga

Dow Jumps 300 Points; Crude Oil Rises Sharply

U.S. stocks traded higher this morning, with the Dow Jones gaining around 300 points on Wednesday.

Benzinga

US Stocks Mixed; Wholesale Inventories Increase 1.3% In August

U.S. stocks traded mixed this morning, with the Dow Jones gaining around 20 points on Wednesday.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2022

Upgrades

The Independent UK

Alzheimer's drug shows promise in early results of study

Shares of Biogen and other drugmakers researching Alzheimer’s disease soared early Wednesday after Japan’s Eisai Co. said its potential treatment appeared to slow the fatal disease’s progress in a late-stage study

The Guardian - UK

Success of experimental Alzheimer’s drug hailed as ‘historic moment’

Study shows cognition in early-stage patients on lecanemab declines by 27% less than those on placebo

1 … 4 5 6 7

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.